Rofecoxib
Links shared publicly online about this topic
CYP450 Metabolite Significantly Increased in Rofecoxib-Treated Mice - QualityPoint Technologies
qualitypointtech.net — “The oral administration of rofecoxib resulted in a significant increase in blood levels of 20-hydroxyeicosatetraenoic acid, a potent vasoconstrictor, and this metabolite was also shown to significantly decrease tail bleeding times in a mouse model. Heartwire” View full resource at qualitypointtech.net
Most Recently Shared on September 17, 2010 at 1:24 am By:
CYP450 Metabolite Significantly Increased in Rofecoxib-Treated Mice: The oral administration of rofecoxib resulted... http://bit.ly/c5wd4k
Diclofenac has same CV risks as withdrawn COX-2 blocker
theheart.org — “A new observational study looking at the entire Danish population has found that the commonly used NSAID diclofenac has similar cardiovascular risks to the withdrawn COX-2 inhibitor rofecoxib, in healthy people. Given that diclofenac is widely used and available over the counter in many countries, these findings are worrying, say the researchers.” View full resource at theheart.org
Most Recently Shared on June 8, 2010 at 8:27 pm By:
Diclofenac: Similar CV risk to rofecoxib in healthy people: A new observational study looking at the entire Danish... http://bit.ly/avXmC4
Medical News: ACR: A Tale of Vioxx, Opioids, and Falls - in Meeting Coverage, ACR from MedPage Today
medpagetoday.com — “ATLANTA -- Pulling rofecoxib (Vioxx) from the market may not have done any favors for elderly patients with osteoarthritis, a researcher suggested here.” View full resource at medpagetoday.com
Most Recently Shared on November 13, 2010 at 8:05 am By:
ACR: A Tale of Vioxx, Opioids, and Falls (CME/CE, with video): ATLANTA (MedPage Today) -- Pulling rofecoxib (Vio... http://bit.ly/bYS62f
Merck defense begins in Oz
theheart.org — “Lawyers for Merck began their defense this week in the rofecoxib class-action lawsuit that is ongoing in Australia. They will have to counter many astonishing allegations that have been made in court in Melbourne over the past few weeks.” View full resource at theheart.org
Most Recently Shared on May 6, 2009 at 2:00 pm By:
heartwire: Merck begins defense in Vioxx case in Australia http://bit.ly/Bpi7s
Konstam responds to <b>heart</b><b><i>wire</i></b>
theheart.org — “Dr Marvin Konstam has countered allegations that he did not significantly contribute to a 2001 Circulation paper on rofecoxib, despite the fact he was its lead author, as reported by heartwire last week.” View full resource at theheart.org
Most Recently Shared on May 8, 2009 at 8:35 pm By:
heartwire: Konstam offers new details on his role in Vioxx meta-analysis http://bit.ly/r8mzh
Which NSAID for heart disease patients?
theheart.org — “One of the first large studies to look at the safety of different NSAIDs specifically in patients with heart disease has found that naproxen appears to have better cardiovascular safety than diclofenac, ibuprofen, and higher doses of rofecoxib and celecoxib.” View full resource at theheart.org
Most Recently Shared on May 28, 2009 at 2:03 pm By:
heartwire: Naproxen best NSAID for heart-disease patients http://bit.ly/FOsRm
Konstam was guest author for Merck
theheart.org — “Prominent cardiologist Dr Marvin Konstam agreed to be lead author on a 2001 Circulation paper about the COX-2 inhibitor rofecoxib, which was written in-house by Merck scientists, according to claims made in a federal court in Australia last week.” View full resource at theheart.org
Most Recently Shared on April 30, 2009 at 10:01 pm By:
heartwire: Fresh questions raised about prominent cardiologist's role in "ghostwritten" 2001 meta-anal.. http://bit.ly/18m4Dz
Early Cardiovascular Risk Revealed By Vioxx Trial Data
medicalnewstoday.com — “Evidence of cardiovascular risks associated with taking vioxx, the popular, nonsteroidal anti-inflammatory drug (rofecoxib), could have been identified nearly four years before its manufacturer, m” View full resource at medicalnewstoday.com
Most Recently Shared on November 25, 2009 at 11:16 am By:
MNT Cardiovascular Health News
Early Cardiovascular Risk Revealed By Vioxx Trial Data: Evidence of cardiovascular risks associated with taking.. http://bit.ly/6G2y1B
Postmarketing lessons from Vioxx
theheart.org — “Data now required by US law could have been put to good use in the Vioxx fiasco, helping researchers confirm the cardiovascular risk with the drug much earlier than it was eventually pinpointed, say the authors of a new analysis.” View full resource at theheart.org
Most Recently Shared on November 23, 2009 at 9:08 pm By:
Postmarketing lessons to learn from Vioxx debacle http://bit.ly/6y7mlf #heartwire
Vioxx harmful even after patients stopped taking it | Reuters
reuters.com — “NEW YORK (Reuters Health) - Merck's withdrawn painkiller Vioxx may have continued to cause blood clots and perhaps deaths even after patients dropped it, U.S. researchers said Monday. The drug was recalled” View full resource at reuters.com
Most Recently Shared on December 14, 2010 at 1:30 am By:
Hisham Rana, MD Doctor and Physician
Study: Vioxx harmful even after patients stopped taking it (Archives of Internal Medicine) http://reut.rs/i7A1sz - #health #pharma
Medical News: CV Risk Remains High After Stopping Vioxx - in Cardiovascular, Venous Thrombosis from MedPage Today
medpagetoday.com — “Even after patients stopped taking the painkiller rofecoxib (Vioxx) when it was pulled from the market, their risk of cardiovascular events remained high, researchers reported.” View full resource at medpagetoday.com
Most Recently Shared on December 14, 2010 at 10:54 pm By:
CV Risk Remains High After Stopping Vioxx (CME/CE): (MedPage Today) -- Even after patients… http://goo.gl/fb/JPtAW
Medical News: CV Risk Remains High After Stopping Vioxx - in Cardiovascular, Venous Thrombosis from MedPage Today
medpagetoday.com — “Even after patients stopped taking the painkiller rofecoxib (Vioxx) when it was pulled from the market, their risk of cardiovascular events remained high, researchers reported.” View full resource at medpagetoday.com
Most Recently Shared on December 14, 2010 at 10:21 pm By:
CV Risk Remains High After Stopping Vioxx (CME/CE) http://bit.ly/dK6hjY
theheart.org: Cardiology news, educational programming, and opinions
feeds.theheart.org — “TheHeart.org is the most trusted source for cardiology news, commentary and continuing medical education on the web.” View full resource at feeds.theheart.org
Most Recently Shared on October 13, 2008 at 11:28 pm By:
New rofecoxib data will help inform treatment decisions with other coxibs, NSAIDs http://tinyurl.com/4typnj
When Pain Relievers Cause Bleeding - Consults Blog - NYTimes.com
consults.blogs.nytimes.com — “All Nsaids, including prescription medications like rofecoxib (Vioxx), celecoxib (Celebrex) and etodolac (Lodine), have the potential to damage the tissue of the gastrointestinal tract.” View full resource at consults.blogs.nytimes.com
Most Recently Shared on April 23, 2010 at 2:52 pm By:
Nicole Kinsey Pet Health Advocate and Active Health Library
When Pain Relievers Cause Bleeding: All Nsaids, including prescription medications like rofecoxib (Vioxx), celecox... http://bit.ly/azYe08
MD Consult: News:
mdconsult.com — “MD Consult: News:” View full resource at mdconsult.com
Most Recently Shared on October 16, 2008 at 10:55 am By:
MD Consult Health Site and Medical Publisher
Final APPROVE trial results confirm rofecoxib raises MI, stroke risks http://tinyurl.com/4jurx5
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
MedicalFeed
Medical news and updates about medical articles and discussion in Google knols and in many medical websites.
-
Shelley Wood
Managing editor for heartwire on theheart.org--the most authoritative, balanced, and insightful cardiovascular disease news online. http://is.gd/nHJ4
-
Osteoporosis_OW
Organizing osteoporosis resources shared by health experts, advocates, and organizations into WisdomCards.
Advertisement
